41![DECISION AID STAGE IV Non-Small Cell Lung Cancer (NSCLC) First-Line Chemotherapy This is a DECISION AID for patients who have Stage IV non-small cell lung cancer (NSCLC) and are trying to decide whether or not to take ch DECISION AID STAGE IV Non-Small Cell Lung Cancer (NSCLC) First-Line Chemotherapy This is a DECISION AID for patients who have Stage IV non-small cell lung cancer (NSCLC) and are trying to decide whether or not to take ch](https://www.pdfsearch.io/img/1f1727cc386efaed78ed4e9efe709f9c.jpg) | Add to Reading ListSource URL: www.asco.orgLanguage: English - Date: 2013-01-18 15:35:17
|
---|
42![New York State Poison Centers The NY State Poison Centers[removed] New York State Poison Centers The NY State Poison Centers[removed]](https://www.pdfsearch.io/img/1d7b8ccddb54e83602bd7cfa554ca108.jpg) | Add to Reading ListSource URL: www.upstate.eduLanguage: English - Date: 2011-06-28 10:31:12
|
---|
43![DECISION AID STAGE IV Non-Small Cell Lung Cancer (NSCLC) Second-Line Chemotherapy This is a DECISION AID for patients who have Stage IV non-small cell lung cancer (NSCLC), and are trying to decide whether or not to take DECISION AID STAGE IV Non-Small Cell Lung Cancer (NSCLC) Second-Line Chemotherapy This is a DECISION AID for patients who have Stage IV non-small cell lung cancer (NSCLC), and are trying to decide whether or not to take](https://www.pdfsearch.io/img/46ddf85b73448e940a44ab309b875899.jpg) | Add to Reading ListSource URL: www.asco.orgLanguage: English - Date: 2013-01-18 15:35:17
|
---|
44![The News Magazine of the International Union of Pure and Applied Chemistry (IUPAC) CHEMISTRY International The News Magazine of the International Union of Pure and Applied Chemistry (IUPAC) CHEMISTRY International](https://www.pdfsearch.io/img/abe5b359e16d112f86563806607d9374.jpg) | Add to Reading ListSource URL: www.iupac.orgLanguage: English - Date: 2011-09-15 06:45:14
|
---|
45![Microsoft Word - Hotline Newsletter[removed]docx Microsoft Word - Hotline Newsletter[removed]docx](https://www.pdfsearch.io/img/5491288d3577c892cc1c3a409016bf0e.jpg) | Add to Reading ListSource URL: www.iowapoison.orgLanguage: English - Date: 2014-10-02 06:02:15
|
---|
46![■ Medical Safety Information Pharmaceuticals and Medical Devices Agency http://www.pmda.go.jp/english/services/safety/medical-info.html ■ Medical Safety Information Pharmaceuticals and Medical Devices Agency http://www.pmda.go.jp/english/services/safety/medical-info.html](https://www.pdfsearch.io/img/deb3f853192f082ac7d492a2d9e30436.jpg) | Add to Reading ListSource URL: www.pmda.go.jpLanguage: English - Date: 2010-10-19 20:45:18
|
---|
47![INSIDE PMB Adios, Amigo! Hola, Girlfriends! In our last issue, we introduced you to our staff. Shortly thereafter, INSIDE PMB Adios, Amigo! Hola, Girlfriends! In our last issue, we introduced you to our staff. Shortly thereafter,](https://www.pdfsearch.io/img/340bf21e2680056d9be9b48dfb58a3ae.jpg) | Add to Reading ListSource URL: ctep.cancer.govLanguage: English - Date: 2008-05-28 21:39:37
|
---|
48![~\,o\\~ ~<-~~ PRINTED: [removed]FORM APPROVED · California Department of Public Health ANO PLAN OF CORRECTION ~\,o\\~ ~<-~~ PRINTED: [removed]FORM APPROVED · California Department of Public Health ANO PLAN OF CORRECTION](https://www.pdfsearch.io/img/49ef776ceb6f1012e722b80659f2c349.jpg) | Add to Reading ListSource URL: www.cdph.ca.govLanguage: English - Date: 2014-01-30 14:45:48
|
---|
49![SPECIFICATIONS cGMP METHOTREXATE USP (S)-2-(4-{[(2,4-Diaminopteridin-6-yl)methyl](methyl)amino}benzamido)pentanedioic acid O NH2 SPECIFICATIONS cGMP METHOTREXATE USP (S)-2-(4-{[(2,4-Diaminopteridin-6-yl)methyl](methyl)amino}benzamido)pentanedioic acid O NH2](https://www.pdfsearch.io/img/90612017302f93f7f2ff5fc23e6605fe.jpg) | Add to Reading ListSource URL: www.biovectra.comLanguage: English - Date: 2013-10-07 16:30:29
|
---|
50![Justified Abbreviated Presentation Criteria MOST of the following criteria are met: •Little if any use • Not marketed • No deaths OR deaths because of underlying disease • Few if any serious adverse event (SAE) r Justified Abbreviated Presentation Criteria MOST of the following criteria are met: •Little if any use • Not marketed • No deaths OR deaths because of underlying disease • Few if any serious adverse event (SAE) r](https://www.pdfsearch.io/img/ee38616be1d75516aeba1f25f617ab21.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English |
---|